Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Letters in Drug Design & Discovery
  4. Volume 21, Issue 16
  5. Article
Volume 21, Issue 16
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Background

DNA methyltransferases (DNMTs) are a group of epigenetic enzymes implicated in regulating gene expression in actively dividing cells. Among these enzymes, DNMT1 plays a leading role in causing increased DNA methylation of tumor suppressors and other genes in cancer cells. This methylation event disrupts the cell cycle regulating genes, allowing an uninterrupted proliferation of cancer cells, and stimulating the inhibition of the degradation of proteins and aberrant transcription activation. Cytosine analog drugs have been shown to reduce DNA methylation but provoke the expression of other prometastatic genes. On the other hand, medicinal compounds act similarly to cytosine analogs by reducing the expression and activity of DNMT1, as reported in some cancer studies. However, it remains a mystery what those promising medicinal compounds are that show such activity.

Objectives

The objective of this study was to screen medicinal compounds that reduce the expression and interact with the active site residues of DNMT1.

Methods

To analyze medicinal compounds against DNMT1, two tools were employed: DIGEP-pred and IGEMDOCK to discover and identify 98 lead medicinal compounds having anticancer potential, capable of regulating DNMT1 expression and activity.

Results

Our results have identified twenty (20) medicinal compounds that reduced the expression of DNMT1 up to 50-77% as compared to the standard cytosine analog (91.5%). These compounds have also interacted with the reported active site residues of DNMT1, as predicted by IGEMDOCK. These compounds have adequate druglikeness, toxicity, and pharmacokinetic properties as described by Protox-II and ADMET lab 2.0.

Conclusion

Thus, our study provides an initial report of those medicinal compounds that have DNMT1 targeting ability and have a relatively safer pharmacokinetic and toxicity profile.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/lddd/10.2174/0115701808265886230921115023
2024-02-09
2024-12-23

  • From This Site

    /content/journals/lddd/10.2174/0115701808265886230921115023
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MurisonK. MichodD. Epigenetic regulation of gene expression.eLS202018
     [Google Scholar]
  2. KagoharaL.T. Stein-O’BrienG.L. KelleyD. FlamE. WickH.C. DanilovaL.V. EaswaranH. FavorovA.V. QianJ. GaykalovaD.A. FertigE.J. Epigenetic regulation of gene expression in cancer: Techniques, resources and analysis.Brief. Funct. Genomics2018171496310.1093/bfgp/elx018 28968850
     [Google Scholar]
  3. CareyN. MarquesC.J. ReikW. DNA demethylases: A new epigenetic frontier in drug discovery.Drug Discov. Today20111615-1668369010.1016/j.drudis.2011.05.004 21601651
     [Google Scholar]
  4. EdwardsJ.R. YarychkivskaO. BoulardM. BestorT.H. DNA methylation and DNA methyltransferases.Epigenetics Chromatin20171012310.1186/s13072‑017‑0130‑8 28503201
     [Google Scholar]
  5. LykoF. The DNA methyltransferase family: A versatile toolkit for epigenetic regulation.Nat. Rev. Genet.2018192819210.1038/nrg.2017.80 29033456
     [Google Scholar]
  6. DanH. ZhangS. ZhouY. GuanQ. DNA methyltransferase inhibitors: Catalysts for antitumour immune responses.OncoTargets Ther.201912109031091610.2147/OTT.S217767 31849494
     [Google Scholar]
  7. NishiyamaA. NakanishiM. Navigating the DNA methylation landscape of cancer.Trends Genet.202137111012102710.1016/j.tig.2021.05.002
     [Google Scholar]
  8. YuJ. XieT. WangZ. WangX. ZengS. KangY. HouT. DNA methyltransferases: Emerging targets for the discovery of inhibitors as potent anticancer drugs.Drug Discov. Today201924122323233110.1016/j.drudis.2019.08.006 31494187
     [Google Scholar]
  9. ChristmanJ.K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy.Oncogene200221355483549510.1038/sj.onc.1205699 12154409
     [Google Scholar]
  10. JoeckelT.E. LübbertM. Clinical results with the DNA hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: An update.Semin. Hematol.201249433034110.1053/j.seminhematol.2012.08.001 23079063
     [Google Scholar]
  11. KarahocaM. MomparlerR.L. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.Clin. Epigenetics201351310.1186/1868‑7083‑5‑3 23369223
     [Google Scholar]
  12. ZhouZ. LiH.Q. LiuF. DNA methyltransferase inhibitors and their therapeutic potential.Curr. Top. Med. Chem.201918282448245710.2174/1568026619666181120150122 30465505
     [Google Scholar]
  13. SchnekenburgerM. LossonH. LernouxM. FloreanC. DicatoM. DiederichM. Natural compounds as epigenetic modulators in cancer.Multidiscip. Digit. Publ. Inst. Proc.20191113010.3390/proceedings2019011030
     [Google Scholar]
  14. ShahF.H. SalmanS. IdreesJ. IdreesF. ShahS.T.A. KhanA.A. AhmadB. Current progress of phytomedicine in glioblastoma therapy.Curr. Med. Sci.20204061067107410.1007/s11596‑020‑2288‑8 33428134
     [Google Scholar]
  15. LvC. WuX. WangX. SuJ. ZengH. ZhaoJ. LinS. LiuR. LiH. LiX. ZhangW. The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: A general template for research on TCMs.Sci. Rep.20177135210.1038/s41598‑017‑00535‑8 28336967
     [Google Scholar]
  16. LaguninA. IvanovS. RudikA. FilimonovD. PoroikovV. DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on structural formula.Bioinformatics201329162062206310.1093/bioinformatics/btt322 23740741
     [Google Scholar]
  17. BanerjeeP. EckertA.O. SchreyA.K. PreissnerR. ProTox-II: A webserver for the prediction of toxicity of chemicals.Nucleic Acids Res.201846W1W257W26310.1093/nar/gky318 29718510
     [Google Scholar]
  18. XiongG. WuZ. YiJ. FuL. YangZ. HsiehC. YinM. ZengX. WuC. LuA. ChenX. HouT. CaoD. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties.Nucleic Acids Res.202149W1W5W1410.1093/nar/gkab255 33893803
     [Google Scholar]
  19. Herrera-AcevedoC. Flores-GasparA. ScottiL. Mendonça-JuniorF.J.B. ScottiM.T. Coy-BarreraE. Identification of kaurane-type diterpenes as inhibitors of leishmania pteridine reductase I.Molecules20212611307610.3390/molecules26113076 34063939
     [Google Scholar]
  20. KarP. SharmaN.R. SinghB. SenA. RoyA. Natural compounds from clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.J. Biomol. Struct. Dyn.20203913112 32552595
     [Google Scholar]
  21. ShahF.H. SalmanS. IdreesJ. IdreesF. AkbarM.Y. In silico study of thymohydroquinone interaction with blood–brain barrier disrupting proteins.Future Sci. OA2020610FSO63210.2144/fsoa‑2020‑0115 33312701
     [Google Scholar]
  22. ShahF.H. KimS.J. Targeting FGL2, a molecular drug target for glioblastoma, with natural compounds through virtual screening method.Future Med. Chem.202113980581610.4155/fmc‑2020‑0331 33821685
     [Google Scholar]
  23. DayJ.K. BauerA.M. desBordesC. ZhuangY. KimB.E. NewtonL.G. NehraV. ForseeK.M. MacDonaldR.S. Besch-WillifordC. HuangT.H.M. LubahnD.B. Genistein alters methylation patterns in mice.J. Nutr.2002132S82419S2423S10.1093/jn/132.8.2419S 12163704
     [Google Scholar]
  24. LeeW.J. ShimJ.Y. ZhuB.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids.Mol. Pharmacol.20056841018103010.1124/mol.104.008367
     [Google Scholar]
  25. QinW. ZhangK. ClarkeK. WeilandT. SauterE.R. Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue.Nutr. Cancer201466227027710.1080/01635581.2014.868910 24447120
     [Google Scholar]
  26. KanwalR. DattM. LiuX. GuptaS. Dietary flavones as dual inhibitors of DNA methyltransferases and histone methyltransferases.PLoS One2016119e016295610.1371/journal.pone.0162956 27658199
     [Google Scholar]
  27. AssumpçãoJ.H.M. TakedaA.A.S. SforcinJ.M. RainhoC.A. Effects of propolis and phenolic acids on triple-negative breast cancer cell lines: Potential involvement of epigenetic mechanisms.Molecules2020256128910.3390/molecules25061289 32178333
     [Google Scholar]
  28. MafiA. RezaeeM. HedayatiN. HoganS.D. ReiterR.J. AarabiM.H. AsemiZ. Melatonin and 5-fluorouracil combination chemo-therapy: Opportunities and efficacy in cancer therapy.Cell Commun. Signal.20232113310.1186/s12964‑023‑01047‑x 36759799
     [Google Scholar]
  29. AndersonG. MaesM. Pharmaceutical and Nutritional Benefits in Alzheimer’s Disease via Convergence on the Melatoninergic Pathways.The NetherlandsBentham Science Publisher Amsterdam20154
     [Google Scholar]
  30. ChenZ. WangK. GuoJ. ZhouJ. LoorJ.J. YangZ. YangY. Melatonin maintains homeostasis and potentiates the anti-inflammatory response in Staphylococcus aureus -induced mastitis through microRNA-16b/YAP1.J. Agric. Food Chem.20227048152551527010.1021/acs.jafc.2c05904 36399659
     [Google Scholar]
  31. XiangS. DauchyR.T. HoffmanA.E. PointerD. FraschT. BlaskD.E. HillS.M. Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.J. Pineal Res.2019672e1258610.1111/jpi.12586 31077613
     [Google Scholar]
  32. ZhaoX.M. WangN. HaoH.S. LiC.Y. ZhaoY.H. YanC.L. WangH.Y. DuW.H. WangD. LiuY. PangY.W. ZhuH.B. Melatonin improves the fertilization capacity and developmental ability of bovine oocytes by regulating cytoplasmic maturation events.J. Pineal Res.2018641e1244510.1111/jpi.12445 28833478
     [Google Scholar]
  33. HeJ. PeiL. JiangH. YangW. ChenJ. LiangH. Chemoresistance of colorectal cancer to 5-fluorouracil is associated with silencing of the BNIP3 gene through aberrant methylation.J. Cancer2017871187119610.7150/jca.18171 28607593
     [Google Scholar]
  34. HartungE.E. MukhtarS.Z. ShahS.M. NilesL.P. 5-Azacytidine upregulates melatonin MT1 receptor expression in rat C6 glioma cells: oncostatic implications.Mol. Biol. Rep.20204764867487310.1007/s11033‑020‑05482‑8 32410138
     [Google Scholar]
/content/journals/lddd/10.2174/0115701808265886230921115023
Loading
Do Anticancer Medicinal Compounds have DNMT1 Regulating Activity: An In silico Investigation
Letters in Drug Design & Discovery 21, 3622 (2024); https://doi.org/10.2174/0115701808265886230921115023
/content/journals/lddd/10.2174/0115701808265886230921115023
/content/journals/lddd/10.2174/0115701808265886230921115023
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Rapid Communication
Keyword(s): ADMET properties; DNA methyltransferases; DNMT1; in silico gene expression; Medicinal compounds; molecular docking

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test